Benzbromarone pharmacokinetics and pharmacodynamics in different cytochrome P450 2C9 genotypes

Drug Metabolism and Pharmacokinetics

Volumn 25, Issue 6, 2010, Pages 605-610

  Uchida, Shinya ^a   Shimada, Kayoko ^a   Misaka, Shingen ^a   Imai, Hiromitsu ^b   Katoh, Yasuhiro ^a   Inui, Naoki ^c   Takeuchi, Kazuhiko ^c   Ishizaki, Takashi ^c   Yamada, Shizuo ^a   Ohashi, Kyoichi ^b   Namiki, Noriyuki ^a   Watanabe, Hiroshi ^c  

^a UNIVERSITY OF SHIZUOKA   (Japan)

^b OITA UNIVERSITY   (Japan)

^c HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Benzbromarone; Cytochrome P450 2C9; Pharmacokinetics; Polymorphism; Uricosuric effect

Indexed keywords

6 HYROXYBENZBROMARONE; BENZBROMARONE; CYTOCHROME P450 2C9; UNCLASSIFIED DRUG; URIC ACID; URICOSURIC AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; GENOTYPE; HOMOZYGOSITY; HUMAN; HUMAN EXPERIMENT; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PHARMACODYNAMICS; PROTEIN FUNCTION; SINGLE DRUG DOSE; URIC ACID BLOOD LEVEL; URIC ACID URINE LEVEL;

EID: 78951490309     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-10-NT-040     Document Type: Article

References (27)

1. Alderman, M. H., Cohen, H., Madhavan, S. and Kivlighn, S.: Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Hypertension, 34: 144-501 (1999).
2. Franse, L. V., Pahor, M., Di Bari, M., Somes, G. W., Cushman, W. C. and Applegate, W. B.: Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program. Hypertension, 35: 1025-1030 (2000).
3. Fang, J. and Alderman, M. H.: Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA, 283: 2404-2410 (2000).
4. Cannon, P. J., Stason, W. B., Demartini, F. E., Sommers, S. C. and Laragh, J. H.: Hyperuricemia in primary and renal hypertension. N. Engl. J. Med., 275: 457-464 (1966).
5. Okura, T., Higaki, J., Kurata, M., Irita, J., Miyoshi, K., Yamazaki, T., Hayashi, D., Kohro, T. and Nagai, R.: Elevated Serum Uric Acid is an Independent Predictor for Cardiovascular Events in Patients With Severe Coronary Artery Stenosis. Circ. J., 73: 885-891 (2009).
6. Culleton, B. F., Larson, M. G., Kannel, W. B. and Levy, D.: Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann. Intern. Med,. 131: 7-13 (1999).
7. Malinow, M. R., Levenson, J., Giral, P., Nieto, F. J., Razavian, M., Segond, P. and Simon, A.: Role of blood pressure, uric acid, and hemorheological parameters on plasma homocyst(e)ine concentration. Atherosclerosis, 114: 175-183, (1995).
8. Heel, R. C., Brogden, R. N., Speight, T. M. and Avery, G. S.: Benzbromarone: a review of its pharmacological properties and therapeutic use in gout and hyperuricaemia. Drugs, 14: 349-366 (1977).
9. Schlesinger, N.: Management of acute and chronic gouty arthritis: present state-of-the-art. Drugs, 64: 2399-2416 (2004).
10. Lee, M. H., Graham, G. G., Williams, K. M. and Day, R. O.: A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients? Drug Saf., 31: 643-665 (2008).
11. WHO Drug Information: Benzbromarone and hepatitis. WHO drug information, 14: 29 (2000).
12. de Vries, A. and Sperling, O.: Inborn hypouricemia due to isolated renal tubular defect. Biomedicine, 30: 75-80 (1979).
13. Enomoto, A., Kimura, H., Chairoungdua, A., Shigeta, Y., Jutabha, P., Cha, S. H., Hosoyamada, M., Takeda, M., Sekine, T., Igarashi, T., Matsuo, H., Kikuchi, Y., Oda, T., Ichida, K., Hosoya, T., Shimokata, K., Niwa, T., Kanai, Y. and Endou, H.: Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature, 417: 447-452 (2002).
14. Walter-Sack, I., de Vries, J. X., Ittensohn, A., Kohlmeier, M. and Weber, E.: Benzbromarone disposition and uricosuric action; evidence for hydroxilation instead of debromination to benzarone. Klin. Wochenschr., 66: 160-166 (1988).
15. De Vries, J. X., Walter-Sack, I., Ittensohn, A. and Weber, E.: The isolation, identification and structure of a new hydroxylated metabolite of benzbromarone in man. Xenobiotica, 19: 1461-1470 (1989).
16. Walter-Sack, I., de Vries, J. X., Ittensohn, A. and Raedsch, R.: Biliary excretion of benzbromarone and its hydroxilated main metabolites in humans. Eur. J. Med. Res., 3: 45-49 (1998).
17. de Vries J. X., Walter-Sack I., Ittensohn A., Weber E., Empl H., Gresser U. and Zoällner N.: Benzbromarone hydroxylation in man: defective formation of the 6-hydroxybenzbromarone metabolite. Clin. Investig., 71: 947-952 (1993).
18. Oikawa, T., Kunishima, C., Adachi, Y., Sato, Y., Okamura, Y., Tanaka, N. and Hosoya, T.: Metabolism study of benzbromarone: In vitro metabolism and pharmacokinetics in healthy volunteers. J. New Rem. & Clin., 53: 682-691 (2004).
19. Kirchheiner, J. and Brockmoller J.: Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin. Pharmacol. Ther., 77: 1-16 (2005).
20. Shon, J. H., Yoon, Y. R., Kim, K. A., Lim, Y. C., Lee, K. J., Park, J. Y., Cha, I. J., Flockhart, D. A. and Shin, J. G.: Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans. Pharmacogenetics, 12: 111-119 (2002).
21. Kirchheiner, J., Brockmoller, J., Meineke, I., Bauer, S., Rohde, W., Meisel, C. and Roots, I.: Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers. Clin. Pharmacol. Ther., 71: 286-296 (2002).
22. Takahashi, H., Kashima, T., Nomizo, Y., Muramoto, N., Shimizu, T., Nasu, K., Kubota, T., Kimura, S. and Echizen, H.: Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes. Clin. Pharmacol. Ther., 63: 519-528 (1998).
23. Walter-Sack, I., de Vries, J. X., Ittensohn, A. and Weber, E.: Rapid and slow benzbromarone elimination phenotypes in man: benzbromarone and metabolite profiles. Eur. J. Clin. Pharmacol,. 39: 577-581 (1990).
24. Sullivan-Klose, T. H., Ghanayem, B. I., Bell, D. A., Zhang, Z. Y., Kaminsky, L. S., Shenfield, G. M., Miners, J. O., Birkett, D. J. and Goldstein, J. A.: The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics, 6: 341-349 (1996).
25. Nasu, K., Kubota, T. and Ishizaki, T.: Genetic analysis of CYP2C9 polymorphism in a Japanese population. Pharmacogenetics, 7: 405-409 (1997).
26. Takahashi, H., Wilkinson, G. R., Caraco, Y., Muszkat, M., Kim, R. B., Kashima, T., Kimura, S. and Echizen, H.: Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanease patients. Clin. Pharmacol. Ther., 73: 253-263 (2003).
27. Kaufmann, P., Torok, M., Hanni, A., Roberts, P., Gasser, R. and Krahenbuhl, S.: Mechanisms of benzarone and benzbromaroneinduced hepatic toxicity. Hepatology, 41: 925-935 (2005).